PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company's pipeline focuses on exon-skipping and related approaches to address genetic muscle and nerve disorders. Its lead candidates include PGN-EDO51, an engineered exon-skipping oligonucleotide in Phase 2 development for Duchenne muscular dystrophy patients amenable to exon 51-skipping, and PGN-EDODM1, a peptide-conjugated antisense oligonucleotide in Phase 2 trials for myotonic dystrophy type 1. The company also maintains a preclinical program, PGN-EDO53, for additional DMD applications.
As a clinical-stage entity, PepGen has not yet generated commercial revenue and operates on a capital-deployment model typical of development-stage biotechnology firms. The company is headquartered in Boston, Massachusetts, and operates with a lean organizational structure of approximately 57 full-time employees. PepGen is incorporated in Delaware and trades on the Nasdaq exchange with a market capitalization of approximately $0.4 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.85 | $-2.85 | +13.6% | |
| 2023 | $-3.30 | $-3.30 | +25.3% | |
| 2022 | $-4.42 | $-4.42 | — |